Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502465 | 0.86 | SLC22A12 (0.46) | XDHCYP1A2CYP2C9CYP2C19SLC22A12 | |
| SCHEMBL7916522 | 0.83 | PLA2G2D (0.44) | XDHSLC22A12 | |
| SCHEMBL7571218 | 0.81 | CDC25B (0.50) | XDHMEN1KMT2A | |
| SCHEMBL16502582 | 0.80 | GRIN2D (0.54) | MCL1TTRPTPRCACMSDMEN1 | |
| SCHEMBL7197446 | 0.79 | TTR (0.46) | TTRPTPRCKMT2A | |
| SCHEMBL250471 | 0.79 | HSD17B10 (0.56) | MCL1TTRPTPRCACMSDMEN1 | |
| SCHEMBL16509448 | 0.78 | PLA2G2D (0.47) | XDHCYP1A2CYP2C9CYP2C19SLC22A12 | |
| SCHEMBL28410867 | 0.77 | MEN1 (0.52) | CYP1A2CYP2C19MCL1ACMSDMEN1 | |
| SCHEMBL11937679 | 0.77 | — | — | |
| SCHEMBL28203557 | 0.76 | CA1 (0.60) | XDHMCL1CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | XDH 786/4885CYP1A2 276/4885CYP2C9 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.